Therapeutics for Macular Degeneration and Other Age

Visgenx is focused on developing gene therapies aimed at treating degenerative retinal diseases, particularly through the modulation of the ELOVL2 gene. This gene plays a crucial role in regulating lipid biosynthesis, which is essential for maintaining the health and function of retinal cells. The company’s lead program targets Dry Age-Related Macular Degeneration (Dry AMD), a condition characterized by the progressive loss of photoreceptor cells and visual acuity. Research indicates that the downregulation of ELOVL2 expression, often exacerbated by DNA methylation as cells age, contributes to the decline in retinal health and function, leading to various visual impairments.

The scientific foundation of Visgenx's approach is based on breakthrough research from the Shiley Eye Institute at the University of California San Diego, which highlights the importance of ELOVL2 in cellular survival and function. The company aims to counteract the effects of aging and cellular senescence by restoring ELOVL2 expression to youthful levels, thereby potentially slowing or halting the progression of not only Dry AMD but also other age-related disorders such as diabetes, osteoporosis, and dementia. Through their innovative therapeutic strategies, Visgenx seeks to improve retinal health and overall quality of life for individuals affected by these conditions.

United States

Visgenx is developing therapeutics based on increasing expression of a gene known as ELOVL2 which has been shown to regulate aging in the retina and other tissues. Our lead indication is Dry Age-Related Macular Degeneration (Dry AMD).

Visgenx

Company Details